1. Any Mood Disorder. National Institute of Mental Health. Accessed July 27, 2020. https://www.nimh.nih.gov/health/statistics/any-mood-disorder.shtml.
2. Depression. The World Health Organization. Accessed July 27, 2020. https://www.who.int/news-room/fact-sheets/detail/depression
3.Funk M, Drew N, Freeman M, Faydi E. Mental Health and Development: Targeting People with Mental Health Conditions as A Vulnerable Group. Geneva, Switzerland: World Health Organization; 2010. https://apps.who.int/iris/handle/10665/44257
4. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459‐480. Doi:10.1016/S1474-4422(18)30499-X https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30499-X/fulltext
5. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3‐14. Doi:10.1602/neurorx.2.1.3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC539316/
6. WHO. Neurological Disorders: Public Health Challenges. Geneva, Switzerland: World Health Organization, WHO Press; 2006. https://www.who.int/mental_health/neurology/neurological_disorders_report_web.pdf
7. Xi J, Zhang Z, Si XA. Improving intranasal delivery of neurological nanomedicine to the olfactory region using magnetophoretic guidance of microsphere carriers. Int J Nanomedicine. 2015;10:1211‐1222. Published 2015 Feb 10. doi:10.2147/IJN.S77520 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334328/